Response rates were 75% first-line and 67% second-line; 79 patients had received the combination by May 15, and global Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results